• 한국식품위생안전성학회지
• /
• 제6권3호
• /
• pp.179-183
• /
• 1991

기니픽과 New Zealand White Rabbits에서 BST에 대한 항원성 시험을 국립보건안전연구원 예규에 따라 1) Active Systemic Anaphylaxis(ASA),2) Passive Systemic Anaphylaxis(PSA),3) Passive Cutaneous Anaphylaxis(PCA) 시험을 실시하여 다음과 같은 결과를 얻었다. 1) ASA, PSA 실험에서 anaphylaxis와 관련된 어떠한 특이적인 임상증상을 나타내지 않아 BST가 기니픽과 토끼에서 anaphylaxis를 유발하지 않는 것으로 생각된다. 2) PCA 실험에서 청색반점과 관찰되지 않은 것으로 보아 BST-specific IgE가 생성되지 않은 것으로 나타났다.

• 생약학회지
• /
• 제25권1호
• /
• pp.35-40
• /
• 1994

Aqueous extreact of fresh ginseng (AFG) was examined for the antigenicity in Hartley guinea pigs in comparision with ovalbumin (OVA). When guinea pigs were sensitized with AFG emulsified with complete Freund's adjuvant (CFA), these animals showed negative reactions in active systemic anaphylaxis (ASA), active cutaneous anaphylaxis (ACA) and passive cutaneous anaphylaxis (PCA) tests and passive hemagglutination (PHA) reaction. On the contrary, when guinea pigs were sensitized with OVA emulsified with CFA as positive controls, these animals disclosed positive reactions in ASA, ACA and PCA tests and PHA reaction. From these results, AFG was considered not to possess antigenic properties in guinea pigs. In addition, the dose levels of AFG empolyed in the present experiment were confirmed not to suppress immune reactions.

• Toxicological Research
• /
• 제19권4호
• /
• pp.321-324
• /
• 2003

Antigenic potential of a novel cephalosporin, IDC7181 was examined a active systemic anaphylaxis (ASA) and passive cutaneous anaphylaxis (PCA) test, in guinea pig and mouse-rat models, respectively. In ASA test, IDC7181 induced the signs of restlessness in a few animals immunized with a high dose (100 mg/kg) of IDC7181 alone or in combination with Freund's complete adjuvant (FCA). In PCA test, only one of ten sera from the animals immunized with a high dose (100 mg/kg) of IDC7181 in the absence or presence of FCA showed positive reaction. The positive reaction, induced by IDC7181, which may be due to $\beta$-lactam ring, in ASA and PCA tests were negligible in comparison with those of traditional cephalosporins. Taken together, it is suggested that IDC7181 do not cause immunological problems in clinical dosage.

• Archives of Pharmacal Research
• /
• 제17권3호
• /
• pp.154-160
• /
• 1994

The antigenicity of the aqueous extract of red ginseng (ARG) was evaluated using the following assay procedures : 1. active systemic anaphylaxis (ASA) in guinea pigs, 2 active cutaneous anaphylaxis (ACA) in guinea pigs, 3 passive cutaneous anaphylaxis (PCA) in guinea pigs, 2.active cutaneous anaphylaxis (ACA) in guinea pigs, 3. passive cutanepous anaphylaxis (PCA) in guina pigs with serum for guina pigs sensitized with ARG and 4. passive hemagglutination (PHA) with serum from guinea pigs sensitized with ARG. 1. ASA : No anaphylaxis reaction was observed in any of the sensitized guinea pigs by elictitation with ARG. 2. ACA : No skin reaction was observed in sensitized guinea pigs after intrademal injection of ARG. 3. PCA in guinea pigs : PCA titer of sera from all the sensitized animals was less than 10 in eliciation with ARG. 4. PHA reaction : When eythrocytes coated with challenge antigen were added to sensitized sera, the hemagglutination titer was less than 1. These results suggest that ARG has no antigenicity under the conditions used. And the dose levels of ARG employed in the present experiment were confirmed not to suppress immune reactions.

• 한국환경성돌연변이발암원학회지
• /
• 제11권2호
• /
• pp.141-147
• /
• 1991

기니픽과 New Zealand White Rabbit에서 PDT-Hepa에 대한 항원성 시험을 실시하였다. 1) Active Systemic Anaphylaxis (ASA), 2) Passive Systemic Anaphylaxis (PSA), 3) Passive Custaneous Anaphylaxis (PCA) 시험을 실시한 결과 ASA, PSA 실험에서 anaphylaxis와 관련된 어떠한 특이적인 임상증상도 나타나지 않아 PDT-Hepa는 기니픽과 토끼에서 항원성이 없는 것으로 보인다. 또한 PCA 실험에서 청색반점이 관찰되지 않은 것으로 보아 PDT-Hepa specific IgE는 생성되지 않는 것으로 판단된다.

• Toxicological Research
• /
• 제16권1호
• /
• pp.83-87
• /
• 2000

This study was carriet out to evaluate the acute intravenous toxicity and antigenicity of Guamerin, newly developed by Mogam Biotechnology Research Institute (MBRI). In acute intravenous toxicity test, ICR mice were administered intravenously with single dose of 1,000mg/kg, and body weights and clinical signs were observed for 14 days. No dead animal, clinical signs, body weight change and abnormal autopsy findings were found in control and Gumerin treated group. Therefore, the 50% lethoal dose (LD50) of Guamerin for ICR mice was more than 1,000mg/kg on intravenous route for male and female. And the antigenic potential of Guamerin was examined by active systemic anaphylaxis(ASA) and passive cutaneous anaphylaxis(PCA) tests. In the ASA test, low and high doses (10 and 100ug/animal, respectiwely) of Guamerin were administed subcutaneously to guinea pigs for 9 times 3 weeks. All experimental groups showed negative responses whereas the positive control group given ovalbumin plus Freunds complete adjuvant (FCA) showed severe anaphylactic responses. PCA test using rats with mice anti-serum against Guamerin, low and high doses(10 and 100 ug/animal, respectively) of Guamerin were administered to mice for 9 times in 3 weeks. The anti-serum against Guamerin was administed intradermally at the back of rats, however, any positive responses were not detected in the experimental groups. These results strongly indicate that Guamerin does not induce IgE production and is not a PCA reaction inducer under these experimental conditions.

• Toxicological Research
• /
• 제11권1호
• /
• pp.157-159
• /
• 1995

A study on antigenicity of HRccine (formalin inactivated HFRS virus vaccine) was investigated in guinea pigs and mice. As a part of the safety evaluation of the HRccine, antigenicity tests were carried out according to the Estabilish Regulations of National Institute of Safety Research. In active systemic anaphylaxis (ASA) test no sign was detected when sensitized with up to 120 clinical dose and challenged with up to 1200 clinical dose in guinea pigs. In passive systemic anaphylaxis test guinea pigs showed no sign. In passive cutaneous anaphylaxis (PCA) test, HRccine specific IgE antibody was not detected when sensitized and challenged with up to 1200 clinical dose. Conclusively, there was no adverse antigenic potential at the clinical dose of 120 clinical dose alone and 120 clinical dose with Al(OH)3.

• Biomolecules & Therapeutics
• /
• 제5권2호
• /
• pp.174-178
• /
• 1997

The immnunogenicity of the possible non-essential component of the combined vaccine (KGCC-957) for the prophylaxis against Japanese encephalitis and Hantaan virus infection recently developed by Korea Green Cross Corporation was investigated using the Hartley guinea pigs. The KGCC-95Vl was administered to the guinea pigs subcutaneously to sensitize the animals. The guinea pigs did not induce any anaphylactic immune responses which could be detectable by the active systemic anaphylaxis (ASA), the passive systemic anaphylaxis (PSA), and the passive cutaneous anaphylaxis (PCA) tests. The KGCC-95Vl is considered not to induce any anaphylactic immune responses except the prophylatic immune effects of the vaccine.

• Toxicological Research
• /
• 제11권1호
• /
• pp.77-80
• /
• 1995

Antigenic potential of genetically-engineered human erythropoietin (EPO) was assessed in guinea pigs (active systemic anaphylaxis [ASA] ; passive cutaneous anaphylaxis [PCA]) and in vitro (hemagglutination test [PHA]). In ASA, EPO at 70~700 U/kg elicited a weak anaphylactic response tvhereas the positive control ovalbumin (OVA) did cause intensive responses leading to death in 40% animals. However, the extract of CHO cells, to which EPO gene was introduced, did not cause any symptom. In PCA and PHA tests, neither EPO nor CHO cell extract induced positive responses. OVA, in contrast, produced high titers in both PCA and PHA tests. It was concluded that, in light of the fact that EPO was slightly antigenic only in ASA but not in PCA or PHA and also that human EPO is a foreign protein to guinea pigs, the present EPO may not be antigenic in humans.

• 생약학회지
• /
• 제46권3호
• /
• pp.203-207
• /
• 2015

This study was performed to examine the antigenic potential of purified bee venom (Apis mellifera L., PBV) collected using bee venom collector. Antigenic potential of PBV was examined by active systemic anaphylaxis (ASA) in guinea pigs. PBV was subcutaneously administered at 0.025 and 0.05 mg/kg and also as a suspension with adjuvant (Freund's complete adjuvant, FCA). Ovalbumin (OVA) as a suspension with adjuvant was used to introduce positive control response. In the weight measurement and clinical observation, experimental groups didn't show any significant changes compared with control group. In the autopsy of body, the abnormalities of lung were detected only in the positive control. In the ASA test, experimental groups didn't show any symptoms of anaphylaxis like piloerection, hyperpnea and staggering gait. These results suggested that PBV didn't have antigenic potential in guinea pig.